Anaphylaxis Management and Prevention

Introduction to Anaphylaxis Treatment

The American Academy of Allergy, Asthma, and Immunology recommends that all patients treated for anaphylaxis must be discharged with two epinephrine auto-injectors, a written emergency action plan, and a mandatory referral to an allergist-immunologist for comprehensive evaluation and trigger identification 1, 2, 3

Patients require individualized observation based on severity and risk factors, with a minimum of 4-6 hours for most cases, extending to prolonged observation or hospital admission for severe reactions or those requiring multiple epinephrine doses 3, 4
The observation period should be at least 4-6 hours for most cases, but may be extended for patients with severe anaphylaxis, cardiovascular comorbidity, or poor self-management skills 4
Biphasic reactions can occur in up to 20% of cases, with risk factors including severe initial presentation, wide pulse pressure, unknown trigger, cutaneous manifestations, and drug triggers in children 4

The American Academy of Allergy, Asthma, and Immunology recommends providing or prescribing two doses of epinephrine auto-injector before discharge, with instructions to carry auto-injectors at all times 3, 5, 6
Patients must be instructed on proper epinephrine self-injection technique and advised to self-inject at the first sign of symptom recurrence, then immediately call an ambulance or proceed to the nearest emergency facility 7

Consider continuation of adjunctive treatment after discharge, including H1 antihistamine, H2 antihistamine, and corticosteroid for 2-3 days, although these medications are not reliable interventions to prevent biphasic anaphylaxis 3, 4

Referral to an allergist-immunologist is mandatory for all patients post-anaphylaxis to identify triggers, coordinate diagnostic testing, and develop long-term management strategies 1, 2, 6
The allergist-immunologist should identify allergic triggers through comprehensive allergy diagnostic testing, including properly timed serum tryptase levels if the diagnosis is uncertain 2, 8

Adolescents and young adults, patients with concomitant asthma, and those with previous anaphylaxis or known allergy to peanuts, tree nuts, fish, or crustacean shellfish are at highest risk for fatal anaphylaxis 6
Patients with cardiovascular disease, those on beta-blockers, and elderly patients are at greater risk for severe reactions and complications 4

Provide printed information about anaphylaxis and its treatment, emphasizing intensive education on specific allergen avoidance based on identified triggers 5, 7
Patients should be advised they are at risk for repeat episodes in the future and must understand the importance of subsequent testing to determine and verify triggers 7

Never discharge patients without epinephrine auto-injectors and proper training, as this is associated with increased mortality 6
Do not rely on antihistamines or corticosteroids alone, as these are adjunctive only and do not prevent biphasic reactions reliably 4
Avoid premature discharge, as observation periods must account for biphasic reaction risk, which can occur up to 72 hours after the initial event 9